1
|
Loxapine-Induced Priapism: A Case Report and Review of the Literature on Antipsychotic-Induced Priapism. Case Rep Psychiatry 2021; 2021:5589967. [PMID: 34336343 PMCID: PMC8302361 DOI: 10.1155/2021/5589967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 06/21/2021] [Accepted: 06/25/2021] [Indexed: 11/17/2022] Open
Abstract
In this case report, a patient with schizophrenia experienced recurrent priapism while undergoing treatment of acute psychosis. This necessitated a review of the emergent treatment of priapism and discussion of the difficulties in treating priapism in a patient with acute psychosis. Therefore, this case report explores multiple possible etiologies of priapism within the realm of psychiatric care, reviews the proposed mechanisms of medication-induced priapism, and considers the psychopharmacological concepts that pertain to antipsychotic selection in the context of antipsychotic-induced priapism.
Collapse
|
2
|
El Jabiry SE, Mansour A, Barrimi M, Oneib B, El Ghazouani F. A very rare case of priapism under aripiprazole in a patient followed for bipolar disorder: A CARE-compliant report. Ann Med Surg (Lond) 2021; 62:216-218. [PMID: 33537133 PMCID: PMC7843361 DOI: 10.1016/j.amsu.2021.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 01/09/2021] [Accepted: 01/09/2021] [Indexed: 11/30/2022] Open
Abstract
INTRODUCTION AND IMPORTANCE Priapism is a urological emergency characterized by abnormally prolonged, painful and irreducible erection. It occurs without a sexual stimulation and habitually exceeds 6 h. About a half of iatrogenic priapisms are believed to be associated with antipsychotics. Until to date, very few cases of aripiprazole-associated priapism were reported. CASE PRESENTATION In this case report, we present the clinical findings of a 40-year-old patient that developed priapism after treatment with aripiprazole after his hospitalization for an episode of clinical mania following treatment discontinuation for bipolar I disorder. The management was successful and priapism was resolved spontaneously. CLINICAL DISCUSSION Despite its low affinity to alpha-1 adrenergic receptors, aripiprazole may be associated with priapism. Several potential factors involved in the pathogenesis of this adverse event have been reported in the literature including history of priapism in a different class of neuroleptics and consumption of psychoactive drugs which are the principal factors found in our case. CONCLUSION Priapism may occur even during treatment with antipsychotics that have a low affinity to alpha1-adrenergic receptors. All patients on antipsychotics should be informed about the risk of this rare but serious adverse event.
Collapse
Affiliation(s)
- Salah-Eddine El Jabiry
- Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco
| | - Atif Mansour
- Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco
| | - Mohammed Barrimi
- Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco
| | - Bouchra Oneib
- Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco
| | - Fatima El Ghazouani
- Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco
| |
Collapse
|
3
|
Montejo AL, de Alarcón R, Prieto N, Acosta JM, Buch B, Montejo L. Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach. J Clin Med 2021; 10:jcm10020308. [PMID: 33467621 PMCID: PMC7829881 DOI: 10.3390/jcm10020308] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Revised: 12/29/2020] [Accepted: 01/08/2021] [Indexed: 12/14/2022] Open
Abstract
Antipsychotic medication can be often associated with sexual dysfunction (SD). Given its intimate nature, treatment emergent sexual dysfunction (TESD) remains underestimated in clinical practice. However, psychotic patients consider sexual issues as important as first rank psychotic symptoms, and their disenchantment with TESD can lead to important patient distress and treatment drop-out. In this paper, we detail some management strategies for TESD from a clinical perspective, ranging from prevention (carefully choosing an antipsychotic with a low rate of TESD) to possible pharmacological interventions aimed at improving patients' tolerability when TESD is present. The suggested recommendations include the following: prescribing either aripiprazole or another dopaminergic agonist as a first option antipsychotic or switching to it whenever possible. Whenever this is not possible, adjunctive treatment with aripiprazole seems to also be beneficial for reducing TESD. Some antipsychotics, like olanzapine, quetiapine, or ziprasidone, have less impact on sexual function than others, so they are an optimal second choice. Finally, a variety of useful strategies (such as the addition of sildenafil) are also described where the previous ones cannot be applied, although they may not yield as optimal results.
Collapse
Affiliation(s)
- Angel L. Montejo
- Psychiatry Service, Clinical Hospital of the University of Salamanca, 37007 Salamanca, Spain;
- Institute of Biomedical Research of Salamanca (IBSAL), Paseo San Vicente SN, 37007 Salamanca, Spain; (J.M.A.); (B.B.)
- Nursing School, University of Salamanca, Av. Donates de Sangre SN, 37007 Salamanca, Spain
- Correspondence: ; Tel.: +34-63-9754-620
| | - Rubén de Alarcón
- Psychiatry Service, Infanta Elena Hospital, Juan Ramon Jiménez Hospital, Ronda Exterior Norte S/N, 21080 Huelva, Spain;
| | - Nieves Prieto
- Psychiatry Service, Clinical Hospital of the University of Salamanca, 37007 Salamanca, Spain;
- Institute of Biomedical Research of Salamanca (IBSAL), Paseo San Vicente SN, 37007 Salamanca, Spain; (J.M.A.); (B.B.)
| | - José Mª Acosta
- Institute of Biomedical Research of Salamanca (IBSAL), Paseo San Vicente SN, 37007 Salamanca, Spain; (J.M.A.); (B.B.)
| | - Bárbara Buch
- Institute of Biomedical Research of Salamanca (IBSAL), Paseo San Vicente SN, 37007 Salamanca, Spain; (J.M.A.); (B.B.)
| | - Laura Montejo
- Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, 08401 Catalonia, Spain;
| |
Collapse
|
4
|
Marrag I, Soussia RB, Hajji K, Zarrouk L, Binous Y, Nasr M. Priapisme induit par la chlorpromazine: A propos de deux cas. AFRICAN JOURNAL OF UROLOGY 2016. [DOI: 10.1016/j.afju.2015.05.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
5
|
Abstract
Human sexuality is contingent upon many biological and psychological factors. Such factors include sexual drive (libido), physiological arousal (lubrication/erection), orgasm, and ejaculation, as well as maintaining normal menstrual cycle. The assessment of sexual dysfunction can be difficult due to the intimate nature of the problem and patients' unwillingness to discuss it. Also, the problem of dysfunction is often overlooked by doctors. Atypical antipsychotic treatment is a key component of mental disorders' treatment algorithms recommended by the National Institute of Health and Clinical Excellence, the American Psychiatric Association, and the British Society for Psychopharmacology. The relationship between atypical antipsychotic drugs and sexual dysfunction is mediated in part by antipsychotic blockade of pituitary dopamine D2 receptors increasing prolactin secretion, although direct correlations have not been established between raised prolactin levels and clinical symptoms. Variety of mechanisms are likely to contribute to antipsychotic-related sexual dysfunction, including hyperprolactinemia, sedation, and antagonism of a number of neurotransmitter receptors (α-adrenergic, dopaminergic, histaminic, and muscarinic). Maintaining normal sexual function in people treated for mental disorders can affect their quality of life, mood, self-esteem, attitude toward taking medication, and compliance during therapy.
Collapse
Affiliation(s)
- Marek J Just
- Department of General and Endocrine Surgery, Piekary Medical Centre, Piekary Slaskie, Poland
| |
Collapse
|
6
|
[Antipsychotic-induced priapism and management challenges: a case report]. Encephale 2014; 40:518-21. [PMID: 24709224 DOI: 10.1016/j.encep.2013.11.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 11/27/2013] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Priapism is a persistent, and often painful, penile erection, lasting more than 3 hours, not usually associated with sexual stimuli. It is a urological emergency that can cause serious complications. Drugs are responsible of the onset of 25 to 40% of cases of priapism. Several classes of medication are involved: antidepressants, antihypertensives, anticoagulants, alpha-blockers and some psychoactive substances (alcohol, cocaine, cannabis...). However, about 50% of drug related priapism is due to antipsychotics (AP). Clinicians should be aware of this rare side effect because of the severity of its complications and the difficulty of its management, especially in non-stabilized psychotic patients. CASE REPORT We report a case of a 22-year-old male Moroccan patient, diagnosed with schizophrenia, who had been admitted for the first time to a psychiatric hospital for management of a psychotic episode. First, he received 15 mg per day of haloperidol, and seven days later he developed priapism. The patient was immediately referred for urological care. Aspiration and irrigation of the corpora cavernosa was proposed, but could not be performed because of patient refusal, and the erection resolved spontaneously after 10 hours. Haloperidol was stopped, and four days later the patient was switched to 10mg per day of olanzapine. After 10 days of treatment, he developed a second episode of priapism, and olanzapine was also stopped. A cavernosal aspiration-irrigation was performed in emergency; which resulted in the partial detumescence of the penis. Two days later, and despite therapeutic abstention, the patient presented another episode of priapism. The indication of a revascularization of the corpora cavernosa was proposed, but again the patient refused the surgery. Finally, the patient was administered 400mg/day of amisulpride, with a favorable outcome. Priapism disappeared after a month with the installation of fibrosis and partial loss of erectile function. DISCUSSION The precise mechanisms of the role of AP in the occurrence of priapism are not all known and a multifactor etiology seems the most likely. Neuromuscular hypothesis is the most mentioned, involving the blocking action of alpha1-adrenergic receptors of the corpora cavernosa for which most of AP have an affinity. The occurrence of priapism in a psychotic patient, especially during periods of decompensation, raises a number of challenges for the medical staff. First, the non-recognition by the patient of this side effect, and its potentially severe consequences. Second, the absence of link between dose and duration of AP treatment on one side, and the onset of priapism on the other, which makes it hard to predict. The third challenge is the choice and initiation of another AP. The literature reveals many cases of priapism in both conventional and atypical AP, the presence of a predisposition to this type of incident has been reported. However, few authors have focused on alternatives to provide for these patients. Amisulpride is currently the only molecule that does not have alpha-adrenergic affinity and is therefore preferred in these cases. CONCLUSION Priapism is a rare but serious adverse event of AP medication. Informing patient about the risk of priapism would help to report it early and prevent erectile dysfunction. Switching to another AP with less alpha1-blocking properties is generally recommended.
Collapse
|
7
|
Karamustafalioglu N, Kalelioglu T, Tanriover O, Gungor FC, Genc A, Ilnem C. A case report of priapism caused by ziprasidon. Psychiatry Investig 2013; 10:425-7. [PMID: 24474994 PMCID: PMC3902163 DOI: 10.4306/pi.2013.10.4.425] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2012] [Revised: 02/07/2013] [Accepted: 02/11/2013] [Indexed: 11/19/2022] Open
Abstract
Priapism is defined as having prolonged (more than 6 h), and usually painful penile erection that occurs without a sexual desire or arousal. Only a very few priapism cases caused by ziprasidone are reported in the literature. In this case report we aimed to present a prolonged penile erection due to use of ziprasidone.
Collapse
Affiliation(s)
- Nesrin Karamustafalioglu
- Department of Psychiatry Bakirkoy Mental Health Training And Research Hospital, Bakirkoy-Istanbul,Turkey
| | - Tevfik Kalelioglu
- Department of Psychiatry Bakirkoy Mental Health Training And Research Hospital, Bakirkoy-Istanbul,Turkey
| | - Ozlem Tanriover
- Department of Family Medicine, Yeditepe University School of Medicine, Kadikoy-Istanbul, Turkey
| | - Ferda Can Gungor
- Department of Psychiatry Bakirkoy Mental Health Training And Research Hospital, Bakirkoy-Istanbul,Turkey
| | - Abdullah Genc
- Department of Psychiatry Bakirkoy Mental Health Training And Research Hospital, Bakirkoy-Istanbul,Turkey
| | - Cem Ilnem
- Department of Psychiatry Bakirkoy Mental Health Training And Research Hospital, Bakirkoy-Istanbul,Turkey
| |
Collapse
|
8
|
Denton K, Kolli V, Sharma A. Ziprasidone-induced ischemic priapism requiring surgical intervention: a case report. Prim Care Companion CNS Disord 2013; 15:12l01443. [PMID: 23724347 DOI: 10.4088/pcc.12l01443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- Kevin Denton
- University of Nebraska Medical Center, Omaha, Nebraska, USA
| | | | | |
Collapse
|
9
|
Dangle PP, Patel MB, Pandya LK, Firlit CF. A modified surgical approach to the Al-Ghorab shunt - an anatomical basis. BJU Int 2012; 109:1872-4. [PMID: 22612336 DOI: 10.1111/j.1464-410x.2012.11253.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Pankaj P Dangle
- Department of Surgery, Division of Urology, Saint Louis University School of Medicine , Saint Louis, MO 63110-0250, USA.
| | | | | | | |
Collapse
|
10
|
Abstract
Sexual dysfunction is a key adverse effect leading to medication noncompliance. Psychotropic drugs associated with sexual dysfunction include antiepileptic drugs, antidepressants, and antipsychotics. Gabapentin, frequently used off-label to treat psychiatric and pain disorders, has previously been reported to cause sexual dysfunction at a minimum total daily dose of 900 mg. This report addresses dose-dependent gabapentin-induced sexual dysfunction reaching total sexual dysfunction (loss of libido, anejaculation, anorgasmia, and impotence) at a total daily dose of only 300 mg.
Collapse
|
11
|
Abstract
INTRODUCTION Ziprasidone is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. The purpose of this review is to assess the overall safety profile of ziprasidone, including its risk for prolonging the electrocardiogram (ECG) QT interval. AREAS COVERED This paper is a review of product labeling and English language reports located through PubMed and information available on regulatory agency websites, with a focus on the safety and tolerability of ziprasidone. EXPERT OPINION Although ziprasidone can prolong the ECG QT interval, this has not resulted in increases in sudden death or cardiac sudden death as noted in a large, simple trial and supported by almost a decade of real-world use in the US. Ziprasidone's principal advantage over some other second-generation antipsychotics has been its overall favorable weight and metabolic profile. Similar to most second-generation antipsychotics, ziprasidone has a lower propensity for extrapyramidal side effects and hyperprolactinemia compared to first-generation antipsychotics.
Collapse
Affiliation(s)
- Leslie Citrome
- New York University School of Medicine, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA.
| |
Collapse
|
12
|
Fischel T, Krivoy A, Brenner I, Weizman A. Priapism as an unusual manifestation of catatonia: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:570. [PMID: 19272314 DOI: 10.1016/j.pnpbp.2009.01.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2008] [Revised: 01/10/2009] [Accepted: 01/11/2009] [Indexed: 12/01/2022]
|
13
|
Abstract
Priapism defined as persistent, painful and prolonged penile erection, was previously thought to be associated only with the use of the older, conventional first generation or typical antipsychotic medications as well as some other medications, notably, trazodone. The mechanism of priapism associated with antipsychotics is not clear but is thought to be related to alpha-adrenergic blockage that is mediated by the alpha receptors in the corpora cavernosa of the penis. Atypical antipsychotics, also known as second-generation antipsychotics, owing to their favorable side effect profile, are being prescribed with increasing frequency and are not as frequently considered to cause priapism. Some case reports reporting this side effect with their use, however, are found. Pubmed and Ovid databases were searched to obtain all articles and case reports of antipsychotic drug-induced priapism. Key search words included 'priapism', 'antipsychotics' and 'drug-induced priapism'. References of all identified studies were also reviewed. A total of 50 publications were obtained. Most of the atypical antipsychotics have been reported to cause priapism. These cases have occurred in patients shortly after having been started on the antipsychotic medications as well as in those who have been on them for an extended period of time without modification in dosage, and have also occurred sometimes, with the addition of another antipsychotic, lithium or serotonin-specific reuptake inhibitor. Priapism has been documented with nearly all the atypical antipsychotic medications. It is, however, a rarely reported side effect and therefore, underappreciated. Priapism can cause irreversible erectile dysfunction and is a urologic emergency. Clinicians should monitor patients on these medications for this rare, yet significant side effect. Furthermore, caution must be used when adding new drugs to the regimen and patients should be closely monitored for this side effect. Educating patients about the risk of developing priapism would help increase awareness of the side effect and promote early reporting thereby, decreasing long-term morbidity.
Collapse
|
14
|
Abstract
The vulnerability and hybrid models for the onset of psychosis are presented. Familial liability, perinatal and developmental factors, and decreased cognitive performance associate with psychosis in adolescence and young adulthood. Genetic predisposition connected with behavioural deviances and/or mental symptoms associate with psychotic development so strongly that monitoring and intervention are indicated. Especially, in families where one or both parents or other family members are severely mentally ill, early family-centred assessments and interventions is needed. Together with familial psychosis, deficits in adolescent and young adult social development indicate thorough assessment, intensive monitoring and often also preventive interventions. During the prodromal phase of psychosis, patients often display unspecific symptoms, such as anxiety and depression, personality disorders, abuse of alcohol or drugs. Social decline, possibly associated with neurocognitive deficits, frequently occurs in the prodromal phase or in the early course of schizophrenia. Among help-seeking patients, occurrence of the Basic Symptoms represent the early initial prodromal state, while the late initial prodome state includes attenuated psychotic symptoms, brief limited intermittent psychotic symptoms, and a first degree relative with psychotic disorder, or a schizotypal personality disorder, together with decrease global functioning. These patients suffer also from other mental symptoms and functional decline, and are clearly in need of psychiatric assessment and treatment. Intervention trials have shown that patients suffering from prodromal syndromes can be successfully treated, and onset of psychosis prevented or delayed. However, more large-scale studies and clinical case descriptions of treatment of patients with sub-threshold psychotic symptoms are needed.
Collapse
|
15
|
Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS DRUG REVIEWS 2007; 13:137-77. [PMID: 17627670 PMCID: PMC6494156 DOI: 10.1111/j.1527-3458.2007.00008.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Ziprasidone is a newer "atypical" or "second-generation" antipsychotic. Oral ziprasidone (ziprasidone hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psychotic features). Ziprasidone intramuscular (ziprasidone mesylate) is FDA-approved for acute agitation in patients with schizophrenia. Oral ziprasidone appears efficacious, and has been shown to have some limited clinical advantages over chlorpromazine and haloperidol in ameliorating negative symptoms of schizophrenia. In Phase 2 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia, ziprasidone did not match the clinical performance of olanzapine and risperidone, appearing closer in overall effectiveness to quetiapine. The rate of dose titration and the dose achieved may have an important bearing on ziprasidone's efficacy profile. In studies of usage for acute agitation in individuals with schizophrenia, intramuscular ziprasidone has been shown to be efficacious and relatively well tolerated. Regarding tolerability, ziprasidone, has important advantages in that it is not associated with clinically significant weight gain or adverse changes in cholesterol, triglycerides, or glycemic control, and patients may experience moderate improvement in these measures when switching to ziprasidone from a different antipsychotic agent. It also lacks significant persistent effects on prolactin levels, is not anticholinergic, and only infrequently causes extrapyramidal side effects or postural hypotension, although it can be associated with somnolence. This tolerability profile may be quite valuable in the treatment of some patients. Ziprasidone may prolong the electrocardiogram (ECG) QTc interval (QT interval corrected for heart rate by a standard algorithm), but after 5 years' clinical availability ziprasidone (by itself) does not appear to pose a substantial clinical problem in this regard. Therefore, ziprasidone may be considered a first-line drug option in the treatment of schizophrenia or manic episodes, but, in view of the differences among antipsychotic medications, drug selection should be guided by the patient's individual characteristics and situation.
Collapse
Affiliation(s)
- William M Greenberg
- Department of Psychiatry, New York University School of Medicine, New York, NY, USA.
| | | |
Collapse
|
16
|
Kaufman KR, Marin H, Menza M. Trazodone and ejaculatory inhibition. JOURNAL OF SEX & MARITAL THERAPY 2007; 33:225-30. [PMID: 17454520 DOI: 10.1080/00926230701267860] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Sexual adverse effects are common with psychotropics. Rational polypharmacy may confound etiology. This case report describes development of ejaculatory inhibition in a male patient with co-morbid psychiatric diagnoses treated with fluoxetine, divalproex sodium, lamotrigine, trazodone, and clonazepam. Detailed psychotropic history with time-line of adverse effect onset implicated trazodone. Within 48 hours of trazodone discontinuation, ejaculatory inhibition was resolved. Clinicians should be aware that trazodone may cause ejaculatory inhibition, understand that determination of sexual adverse effects necessitates directed and periodic questioning as these symptoms may increase in severity over time, and appreciate that religious patients may find discussing this issue difficult.
Collapse
Affiliation(s)
- Kenneth R Kaufman
- Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
| | | | | |
Collapse
|
17
|
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2006. [DOI: 10.1002/pds.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|